Atypical antipsychotic agents, retinopathy, nephropathy, and cardiovascular disease

Diabetes Care

Volumn 29, Issue 6, 2006, Pages 1439-1446

  Bloomgarden, Zachary T ^a,b  

^a Mount Sinai School of Medicine ^*

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ARIPIPRAZOLE; ATORVASTATIN; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOFIBRATE; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLICLAZIDE; GROWTH FACTOR; HALOPERIDOL; INSULIN; LISINOPRIL; LOSARTAN; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; OLMESARTAN; QUETIAPINE; QUINAPRIL; RISPERIDONE; ROSIGLITAZONE; SALAZOSULFAPYRIDINE; SALICYLATE SODIUM; SIMVASTATIN; SULFONYLUREA; UNINDEXED DRUG; ZIPRASIDONE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; SIDE EFFECT; STENT; WEIGHT GAIN;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HUMANS;

EID: 33746467087     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0006     Document Type: Conference Paper

References (12)

1. Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM: Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 58:565-572, 2001
2. Osby U, Correia N, Brandt L, Ekbom A, Sparen P: Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45:21-28, 2000
3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696, 1999
4. US Food and Drug Administration: 2004 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements [article online]. Available from http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm
5. Lund BC, Perry PJ, Brooks JM, Arndt S: Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 58:1172-1176, 2001
6. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561-566, 2002
7. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325:243, 2002
8. Gianfrancesco F, White R, Wang RH, Nasrallah HA: Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 23:328-335, 2003
9. Caro JJ, Ward A, Levinton C, Robinson K: The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63:1135-1139, 2002
10. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L: A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56:164-170, 2003
11. The American Diabetes Association, the American Psychiatric Association, the American Association of Clinical Endocrinologists, the North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes (Review). Diabetes Care 27:596-601, 2004
12. Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15:815-819, 1992